Dr. William I. Bensinger, MD, Fred Hutchinson Cancer Research Center, University of Washington Interview date: August 30, 2013
On this week's show, Dr. William Bensinger reviews the many approaches at the Fred Hutchinson Cancer Research Center to both improve care and move towards a cure for myeloma. He describes several early studies happening including the monoclonal antibody drug elotuzumab, which targets the CS1 protein and has had impressive results in combination with other therapies like lenalidomide and dex. He describes several carfilzomib trials and how it is now being studied in combination with other therapies with and without autologous transplantation. He describes two new oral proteasome inhibitors - oprozomib (an oral form of carfilzomib) and ixazomib (an oral form of bortezomib). He describes the potential for an anti-CD38 antibody as single agent to fight myeloma using daratumumab and other anti CD-38 approaches. He describes a new histone deacetylase inhibitor called ACY-1215, and describes how a new radioisotope called Yttrium-90 attached to a CD45 antibody is being used before allogeneic transplantation for patients with highly aggressive myeloma. He also discusses some of the pros and cons of allogeneic vs. autologous transplantation. The live mPatient Radio podcast with Dr. Bensinger
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113